Can we predict which patients will benefit from Tarceva based on a blood test?
12 giu 2013 ·
7 min. 54 sec.
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to...
mostra di più
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
mostra meno
Informazioni
| Autore | cancerGRACE |
| Organizzazione | cancerGRACE |
| Sito | - |
| Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
